Cases & Deals

Johnson & Johnson announces $438 million acquisition of Omrix Biopharmaceuticals

Clients Johnson & Johnson

Jones Day acted as tax counsel to Johnson & Johnson in its approximately $438 million acquisition of Omrix Biopharmaceuticals, Inc., a fully integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products. The acquisition was completed on December 30, 2008.